Genome-wide CRISPR Screen in a Mouse Model of Tumor Growth and Metastasis
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Researchers have used CRISPR systems to study the impact of specific genes on cancer progression.
“as well as to study the impact of specific genes on the progression of the disease [158,159].”
From CRISPR-Cas: Converting A Bacterial Defence Mechanism into A State-of-the-Art Genetic Manipulation Tool (2019) · cites this paper as [159]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
Cutadapt removes adapter sequences from high-throughput sequencing reads
Martin, M. (2011) · EMBnet.journal · doi:10.14806/ej.17.1.200 · Cited by 33,889
Ultrafast and memory-efficient alignment of short DNA sequences to the human genome.
Langmead, B., Trapnell, C., Pop, M., & Salzberg, S. L. (2009) · Genome Biology · doi:10.1186/gb-2009-10-3-r25 · Cited by 21,849
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455
A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity
Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012) · Science · doi:10.1126/science.1225829 · Cited by 17,116
Multiplex Genome Engineering Using CRISPR/Cas Systems
Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A., et al. (2013) · Science · doi:10.1126/science.1231143 · Cited by 15,339
Self-citationRNA-Guided Human Genome Engineering via Cas9
Mali, P., Yang, L., Esvelt, K. M., Aach, J., Guell, M., DiCarlo, J. E., Norville, J. E., & Church, G. M. (2013) · Science · doi:10.1126/science.1232033 · Cited by 9,210
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A. A., Kim, S., Wilson, C. J., Lehár, J., Kryukov, G. V., Sonkin, D., et al. (2012) · Nature · doi:10.1038/nature11003 · Cited by 7,950
Comprehensive molecular profiling of lung adenocarcinoma
The Cancer Genome Atlas Research Network (2014) · Nature · doi:10.1038/nature13385 · Cited by 5,732
Genome-scale CRISPR-Cas9 knockout screening in human cells
Shalem, O., Sanjana, N. E., Hartenian, E., Shi, X., Scott, D. A., Mikkelsen, T. S., Heckl, D., Ebert, B. L., Root, D. E., Doench, J. G., et al. (2014) · Science · doi:10.1126/science.1247005 · Cited by 5,234
Self-citationDNA targeting specificity of RNA-guided Cas9 nucleases
Hsu, P. D., Scott, D. A., Weinstein, J. A., Ran, F. A., Konermann, S., Agarwala, V., Li, Y., Fine, E. J., Wu, X., Shalem, O., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2647 · Cited by 4,741
Self-citationComprehensive genomic characterization of squamous cell lung cancers
The Cancer Genome Atlas Research Network (2012) · Nature · doi:10.1038/nature11404 · Cited by 3,994
Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex
Konermann, S., Brigham, M. D., Trevino, A. E., Joung, J., Abudayyeh, O. O., Barcena, C., Hsu, P. D., Habib, N., Gootenberg, J. S., Nishimasu, H., et al. (2015) · Nature · doi:10.1038/nature14136 · Cited by 2,825 · cited 1×
“Other screening technologies, such as Cas9-mediated activation (Gilbert et al., 2014; Konermann et al., 2015), can identify metastasis-regulating factors that act in a gain-of-function manner.”
BackgroundSelf-citationGenome-Scale CRISPR-Mediated Control of Gene Repression and Activation
Gilbert, L. A., Horlbeck, M. A., Adamson, B., Villalta, J. E., Chen, Y., Whitehead, E. H., Guimaraes, C., Panning, B., Ploegh, H. L., Bassik, M. C., et al. (2014) · Cell · doi:10.1016/j.cell.2014.09.029 · Cited by 2,728
CRISPR RNA Maturation by Trans-Encoded Small RNA and Host Factor RNase III
Deltcheva, E., Chylinski, K., Sharma, C. M., Gonzales, K., Chao, Y., Pirzada, Z. A., Eckert, M. R., Vogel, J., & Charpentier, E. (2011) · Nature · doi:10.1038/nature09886 · Cited by 2,563
Koike-Yusa, H., Li, Y., Tan, E.-P., Velasco-Herrera, M. D. C., & Yusa, K. (2014) · Nature Biotechnology · doi:10.1038/nbt.2800 · Cited by 1,064
KRAS and YAP1 Converge to Regulate EMT and Tumor Survival
Shao, D. D., Xue, W., Krall, E. B., Bhutkar, A., Piccioni, F., Wang, X., Schinzel, A. C., Sood, S., Rosenbluh, J., Kim, J. W., et al. (2014) · Cell · doi:10.1016/j.cell.2014.06.004 · Cited by 744
Flagged first, then by citations
Research works printed but not linked: 39
- Aceto, 2014, Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis, Cell, 158, 1110, 10.1016/j.cell.2014.07.013 · DOI
- Barrangou, 2007, CRISPR provides acquired resistance against viruses in prokaryotes, Science, 315, 1709, 10.1126/science.1138140 · DOI · Paper page
- Bolotin, 2005, Clustered regularly interspaced short palindrome repeats (CRISPRs) have spacers of extrachromosomal origin, Microbiology, 151, 2551, 10.1099/mic.0.28048-0 · DOI
- Chen, 2014, Global microRNA depletion suppresses tumor angiogenesis, Genes Dev., 28, 1054, 10.1101/gad.239681.114 · DOI
- Cheng, 2014, MiR-152 suppresses the proliferation and invasion of NSCLC cells by inhibiting FGF2, Exp. Mol. Med., 46, e112, 10.1038/emm.2014.51 · DOI
- Chylinski, 2013, The tracrRNA and Cas9 families of type II CRISPR-Cas immunity systems, RNA Biol., 10, 726, 10.4161/rna.24321 · DOI · Paper page
- Chylinski, 2014, Classification and evolution of type II CRISPR-Cas systems, Nucleic Acids Res., 42, 6091, 10.1093/nar/gku241 · DOI · Paper page
- Francia, 2011, Mouse models of advanced spontaneous metastasis for experimental therapeutics, Nat. Rev. Cancer, 11, 135, 10.1038/nrc3001 · DOI
- Gao, 2013, Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal, Sci. Signal., 6, p11, 10.1126/scisignal.2004088 · DOI · Paper page
- Garneau, 2010, The CRISPR/Cas bacterial immune system cleaves bacteriophage and plasmid DNA, Nature, 468, 67, 10.1038/nature09523 · DOI
- Garraway, 2013, Lessons from the cancer genome, Cell, 153, 17, 10.1016/j.cell.2013.03.002 · DOI
- Gasiunas, 2012, Cas9-crRNA ribonucleoprotein complex mediates specific DNA cleavage for adaptive immunity in bacteria, Proc. Natl. Acad. Sci. USA, 109, E2579, 10.1073/pnas.1208507109 · DOI · Paper page
- Heimann, 1998, Aging, progression, and phenotype in breast cancer, J. Clin. Oncol., 16, 2686, 10.1200/JCO.1998.16.8.2686 · DOI
- Huang, 2012, MED12 controls the response to multiple cancer drugs through regulation of TGF-β receptor signaling, Cell, 151, 937, 10.1016/j.cell.2012.10.035 · DOI · Paper page
- Jesien-Lewandowicz, 2009, High incidence of MGMT promoter methylation in primary glioblastomas without correlation with TP53 gene mutations, Cancer Genet. Cytogenet., 188, 77, 10.1016/j.cancergencyto.2008.09.015 · DOI
- Kaczmarczyk, 2012, Cytological examination of pleural cavity lavage accompanied by the study of gene promoter hypermethylation of p16 and O6-methylguanine-DNA-methyltransferase genes in diagnostics of non-small cell lung cancer metastatic changes into pleura, Contemp Oncol (Pozn), 16, 322
- Korczak, 1988, Genetic tagging of tumor cells with retrovirus vectors: clonal analysis of tumor growth and metastasis in vivo, Mol. Cell. Biol., 8, 3143, 10.1128/MCB.8.8.3143 · DOI
- Kumar, 2009, Dicer1 functions as a haploinsufficient tumor suppressor, Genes Dev., 23, 2700, 10.1101/gad.1848209 · DOI
- Lawrence, 2013, Mutational heterogeneity in cancer and the search for new cancer-associated genes, Nature, 499, 214, 10.1038/nature12213 · DOI · Paper page
- Lohr, 2014, Whole-exome sequencing of circulating tumor cells provides a window into metastatic prostate cancer, Nat. Biotechnol., 32, 479, 10.1038/nbt.2892 · DOI
- McClatchey, 1998, Mice heterozygous for a mutation at the Nf2 tumor suppressor locus develop a range of highly metastatic tumors, Genes Dev., 12, 1121, 10.1101/gad.12.8.1121 · DOI
- McFadden, 2014, Genetic and clonal dissection of murine small cell lung carcinoma progression by genome sequencing, Cell, 156, 1298, 10.1016/j.cell.2014.02.031 · DOI
- Nguyen, 2009, Metastasis: from dissemination to organ-specific colonization, Nat. Rev. Cancer, 9, 274, 10.1038/nrc2622 · DOI
- Rouet, 1994, Introduction of double-strand breaks into the genome of mouse cells by expression of a rare-cutting endonuclease, Mol. Cell. Biol., 14, 8096, 10.1128/MCB.14.12.8096 · DOI
- Sanjana, 2014, Improved vectors and genome-wide libraries for CRISPR screening, Nat. Methods, 11, 783, 10.1038/nmeth.3047 · DOI · Paper page
- Sapranauskas, 2011, The Streptococcus thermophilus CRISPR/Cas system provides immunity in Escherichia coli, Nucleic Acids Res., 39, 9275, 10.1093/nar/gkr606 · DOI
- Schiano, 2014, Involvement of Mediator complex in malignancy, Biochim. Biophys. Acta, 1845, 66
- Schramek, 2014, Direct in vivo RNAi screen unveils myosin IIa as a tumor suppressor of squamous cell carcinomas, Science, 343, 309, 10.1126/science.1248627 · DOI
- Tang, 2011, MicroRNA 345, a methylation-sensitive microRNA is involved in cell proliferation and invasion in human colorectal cancer, Carcinogenesis, 32, 1207, 10.1093/carcin/bgr114 · DOI
- Tano, 1990, Isolation and structural characterization of a cDNA clone encoding the human DNA repair protein for O6-alkylguanine, Proc. Natl. Acad. Sci. USA, 87, 686, 10.1073/pnas.87.2.686 · DOI
- Valastyan, 2011, Tumor metastasis: molecular insights and evolving paradigms, Cell, 147, 275, 10.1016/j.cell.2011.09.024 · DOI · Paper page
- Vanharanta, 2013, Origins of metastatic traits, Cancer Cell, 24, 410, 10.1016/j.ccr.2013.09.007 · DOI · Paper page
- Waghorne, 1988, Genetic evidence for progressive selection and overgrowth of primary tumors by metastatic cell subpopulations, Cancer Res., 48, 6109
- Wang, 2014, Genetic screens in human cells using the CRISPR-Cas9 system, Science, 343, 80, 10.1126/science.1246981 · DOI · Paper page
- Yokota, 2003, Genetic alterations responsible for metastatic phenotypes of lung cancer cells, Clin. Exp. Metastasis, 20, 189, 10.1023/A:1022978932215 · DOI
- Zender, 2008, An oncogenomics-based in vivo RNAi screen identifies tumor suppressors in liver cancer, Cell, 135, 852, 10.1016/j.cell.2008.09.061 · DOI
- Zhou, 2014, High-throughput screening of a CRISPR/Cas9 library for functional genomics in human cells, Nature, 509, 487, 10.1038/nature13166 · DOI · Paper page
- Chung, 2013, Rare cell isolation and profiling on a hybrid magnetic/size-sorting chip, Biomicrofluidics, 7, 54107, 10.1063/1.4821923 · DOI
- Platt, 2014, CRISPR-Cas9 knockin mice for genome editing and cancer modeling, Cell, 159, 440, 10.1016/j.cell.2014.09.014 · DOI · Paper page
Cited by
Sorted by citations
In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target
Manguso, R. T., Pope, H. W., Zimmer, M. D., Brown, F. D., Yates, K. B., Miller, B. C., Collins, N. B., Bi, K., LaFleur, M. W., Juneja, V. R., et al. (2017) · Nature · doi:10.1038/nature23270 · Cited by 1,147
Genome-scale CRISPR-Cas9 Knockout and Transcriptional Activation Screening
Joung, J., Konermann, S., Gootenberg, J. S., Abudayyeh, O. O., Platt, R. J., Brigham, M. D., Sanjana, N. E., & Zhang, F. (2017) · Nature Protocols · doi:10.1038/nprot.2017.016 · Cited by 1,243
Self-citationHorlbeck, M. A., Gilbert, L. A., Villalta, J. E., Adamson, B., Pak, R. A., Chen, Y., Fields, A. P., Park, C. Y., Corn, J. E., Kampmann, M., et al. (2016) · eLife · doi:10.7554/elife.19760 · Cited by 894
BCL11A enhancer dissection by Cas9-mediated in situ saturating mutagenesis
Canver, M. C., Smith, E. C., Sher, F., Pinello, L., Sanjana, N. E., Shalem, O., Chen, D. D., Schupp, P. G., Vinjamur, D. S., Garcia, S. P., et al. (2015) · Nature · doi:10.1038/nature15521 · Cited by 886
Self-citationA major chromatin regulator determines resistance of tumor cells to T cell–mediated killing
Pan, D., Kobayashi, A., Jiang, P., Ferrari de Andrade, L., Tay, R. E., Luoma, A. M., Tsoucas, D., Qiu, X., Lim, K., Rao, P., et al. (2018) · Science · doi:10.1126/science.aao1710 · Cited by 852
Identification of essential genes for cancer immunotherapy
Patel, S. J., Sanjana, N. E., Kishton, R. J., Eidizadeh, A., Vodnala, S. K., Cam, M., Gartner, J. J., Jia, L., Steinberg, S. M., Yamamoto, T. N., et al. (2017) · Nature · doi:10.1038/nature23477 · Cited by 870
Self-citationDissecting Immune Circuits by Linking CRISPR-Pooled Screens with Single-Cell RNA-Seq
Jaitin, D. A., Weiner, A., Yofe, I., Lara-Astiaso, D., Keren-Shaul, H., David, E., Salame, T. M., Tanay, A., van Oudenaarden, A., & Amit, I. (2016) · Cell · doi:10.1016/j.cell.2016.11.039 · Cited by 777
Preclinical Mouse Cancer Models: A Maze of Opportunities and Challenges
Day, C.-P., Merlino, G., & Van Dyke, T. (2015) · Cell · doi:10.1016/j.cell.2015.08.068 · Cited by 676
Delivery strategies of the CRISPR-Cas9 gene-editing system for therapeutic applications
Liu, C., Zhang, L., Liu, H., & Cheng, K. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.09.012 · Cited by 607
Wang, H.-X., Li, M., Lee, C. M., Chakraborty, S., Kim, H.-W., Bao, G., & Leong, K. W. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.6b00799 · Cited by 560
Miller, J. B., Zhang, S., Kos, P., Xiong, H., Zhou, K., Perelman, S. S., Zhu, H., & Siegwart, D. J. (2017) · Angewandte Chemie International Edition · doi:10.1002/anie.201610209 · Cited by 540
Applications of the CRISPR-Cas9 system in cancer biology
Sánchez-Rivera, F. J., & Jacks, T. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3950 · Cited by 405
Wei, L., Lee, D., Law, C.-T., Zhang, M. S., Shen, J., Chin, D. W.-C., Zhang, A., Tsang, F. H.-C., Wong, C. L.-S., Ng, I. O.-L., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12606-7 · Cited by 428
CRISPR screens in cancer spheroids identify 3D growth-specific vulnerabilities
Han, K., Pierce, S. E., Li, A., Spees, K., Anderson, G. R., Seoane, J. A., Lo, Y.-H., Dubreuil, M., Olivas, M., Kamber, R. A., et al. (2020) · Nature · doi:10.1038/s41586-020-2099-x · Cited by 311
Self-citationGut-licensed IFNγ+ NK cells drive LAMP1+TRAIL+ anti-inflammatory astrocytes
Sanmarco, L. M., Wheeler, M. A., Gutiérrez-Vázquez, C., Polonio, C. M., Linnerbauer, M., Pinho-Ribeiro, F. A., Li, Z., Giovannoni, F., Batterman, K. V., Scalisi, G., et al. (2021) · Nature · doi:10.1038/s41586-020-03116-4 · Cited by 331
CRISPR Ethics: Moral Considerations for Applications of a Powerful Tool
Brokowski, C., & Adli, M. (2019) · Journal of Molecular Biology · doi:10.1016/j.jmb.2018.05.044 · Cited by 320
A new era in functional genomics screens
Przybyla, L., & Gilbert, L. A. (2022) · Nature Reviews Genetics · doi:10.1038/s41576-021-00409-w · Cited by 281
Translational value of mouse models in oncology drug development
Gould, S. E., Junttila, M. R., & de Sauvage, F. J. (2015) · Nature Medicine · doi:10.1038/nm.3853 · Cited by 293
Targeted Perturb-seq enables genome-scale genetic screens in single cells
Schraivogel, D., Gschwind, A. R., Milbank, J. H., Leonce, D. R., Jakob, P., Mathur, L., Korbel, J. O., Merten, C. A., Velten, L., & Steinmetz, L. M. (2020) · Nature Methods · doi:10.1038/s41592-020-0837-5 · Cited by 245
Gasperini, M., Findlay, G. M., McKenna, A., Milbank, J. H., Lee, C., Zhang, M. D., Cusanovich, D. A., & Shendure, J. (2017) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2017.06.010 · Cited by 143
Collateral lethality: a new therapeutic strategy in oncology
Muller, F. L., Aquilanti, E. A., & DePinho, R. A. (2015) · Trends in Cancer · doi:10.1016/j.trecan.2015.10.002 · Cited by 132
Loureiro, A., & da Silva, G. J. (2019) · Antibiotics · doi:10.3390/antibiotics8010018 · Cited by 129
Predicting and characterizing a cancer dependency map of tumors with deep learning
Chiu, Y.-C., Zheng, S., Wang, L.-J., Iskra, B. S., Rao, M. K., Houghton, P. J., Huang, Y., & Chen, Y. (2021) · Science Advances · doi:10.1126/sciadv.abh1275 · Cited by 84
“However, such a screen remains challenging and costly and can only be carried out in few mouse models (38, 39).”
BackgroundGuide Swap enables genome-scale pooled CRISPR-Cas9 screening in human primary cells
Ting, P. Y., Parker, A. E., Lee, J. S., Trussell, C., Sharif, O., Luna, F., Federe, G., Barnes, S. W., Walker, J. R., Vance, J., et al. (2018) · Nature Methods · doi:10.1038/s41592-018-0149-1 · Cited by 80
Feldman, D., Singh, A., Garrity, A. J., & Blainey, P. C. (2018) · doi:10.1101/262121 · Cited by 49
Genome engineering of stem cell organoids for disease modeling
Sun, Y., & Ding, Q. (2017) · Protein & Cell · doi:10.1007/s13238-016-0368-0 · Cited by 39
CRISP-view: a database of functional genetic screens spanning multiple phenotypes
Cui, Y., Cheng, X., Chen, Q., Song, B., Chiu, A., Gao, Y., Dawson, T., Chao, L., Zhang, W., Li, D., et al. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkaa809 · Cited by 24
Binan, L., Danquah, S., Valakh, V., Simonton, B., Bezney, J., Nehme, R., Cleary, B., & Farhi, S. L. (2023) · doi:10.1101/2023.11.30.569494 · Cited by 139
Metadata
- Authors
- Chen, S., Sanjana, N. E., Zheng, K., Shalem, O., Lee, K., Shi, X., Scott, D. A., Song, J., Pan, J. Q., Weissleder, R., Lee, H., Zhang, F., & Sharp, P. A.
- Venue
- Cell
- Publisher
- Elsevier BV
- Published
- 2015-03
- Volume
- 160
- Issue
- 6
- Pages
- 1246-1260
- ISSN
- 0092-8674
- PMC
- PMC4380877
- Cited by
- 862
- References
- 18
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
